Radiopharmacy firm Syncor last week announced changes in its relationships with suppliers AmershamMedi-Physics and Du Pont Merck Pharmaceutical that will affectthe company's 1995 financial performance. Syncor, of Chatsworth,CA, said that Medi-Physics has
Radiopharmacy firm Syncor last week announced changes in its relationships with suppliers AmershamMedi-Physics and Du Pont Merck Pharmaceutical that will affectthe company's 1995 financial performance. Syncor, of Chatsworth,CA, said that Medi-Physics has stopped selling its radiopharmaceuticalproducts through Syncor's network. The decision was effectiveJan. 16 and is due to a distribution alliance Medi-Physics formedlate last year with Mallinckrodt Medical and Geodax Technologies(SCAN 12/28/94). Syncor earned about $2.4 million in operatingincome from sales of Medi-Physics products in 1994.
On a positive note, Syncor has restructured its distributionrelationship with Du Pont Merck, which the companies entered intolast year (SCAN 1/19/94). The costs of the alliance have provedhigher than expected and have reduced Syncor's margins from the30% range to 20%, according to the company. As a result, Syncorand Du Pont Merck restructured their pricing agreement to evenout the costs of distribution. The alliance was responsible for$64 million in new sales last year, Syncor reported.
Also under the terms of the alliance, Syncor began distributingDu Pont Merck's Neurolite product, which received Food and DrugAdministration approval last year (SCAN 12/14/94). Syncor haspreferential distribution rights for the brain SPECT imaging agent.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.